Regulator flags gaps in Bharat Biotech's TB vaccine trial

The decision delays regulatory approval for Bharat Biotech’s proposed phase III trial of MTBVAC, one of the world’s most advanced tuberculosis vaccine candidates and a potential successor to the century-old BCG.